 

Active Ingredient: Betamethasone dipropionate 

 

Dosage Form; Route: Cream (augmented); topical 

 

Recommended Studies: Two studies 

 

1. Type of study: Pilot vasoconstrictor study 


Design: Pilot dose duration-response study using the reference product under un-
occluded condition 

Strength: 0.05% 

Subjects: Healthy males and females (non-pregnant, non-lactating), general population 

Additional comments: Refer to the guidance “Topical Dermatological Corticosteroids: In 
Vivo Bioequivalence” available at: 

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070234.pdf. 

 

 

2. Type of study: Pivotal vasoconstrictor study 


Design: Pivotal in vivo bioequivalence study under un-occluded condition 

Strength: 0.05% 

Subjects: Healthy males and females (non-pregnant, non-lactating), general population 

Additional comments: See comments above. 

 

 

Analytes to measure (in appropriate biological fluid): Not applicable 

 

Bioequivalence based on (90% CI): Pivotal vasoconstrictor study 

 

Waiver request of in vivo testing: Not applicable 

Dissolution test method and sampling times: Not applicable 


